In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Companies Look West, East, Anyplace But US

Executive Summary

With clear regulatory approval paths in Europe and growing markets in Asia and other developing markets, device executives and investors see international markets as increasingly attractive alternatives for clinical validation, revenue, and regulatory approval.
Advertisement

Related Content

Kanghui: A New Strategic Opens The Door To Orthopedics In China
At PCR, Interventional Cardiology Looks East, Not West
At PCR, Interventional Cardiology Looks East Not West
Rox Gets Blood Pumping in COPD
Pulmonary Device Companies Take It To The Streets - In Europe
Essex Woodlands Partners With Lemaitre to Start White Pine
China's Health Care Reform: Bull Run for Medtech Starts in the Year of the Ox
Ablation Frontiers: Making AF Ablation Simple and Universal
Rox Breathes Easy
China: The Wild, Wild East for Medical Devices

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel